Stairley, R.A.; Trouten, A.M.; Li, S.; Roddy, P.L.; DeLeon-Pennell, K.Y.; Lee, K.-H.; Sucov, H.M.; Liu, C.; Tao, G.
Anti-Ferroptotic Treatment Deteriorates Myocardial Infarction by Inhibiting Angiogenesis and Altering Immune Response. Antioxidants 2024, 13, 769.
https://doi.org/10.3390/antiox13070769
AMA Style
Stairley RA, Trouten AM, Li S, Roddy PL, DeLeon-Pennell KY, Lee K-H, Sucov HM, Liu C, Tao G.
Anti-Ferroptotic Treatment Deteriorates Myocardial Infarction by Inhibiting Angiogenesis and Altering Immune Response. Antioxidants. 2024; 13(7):769.
https://doi.org/10.3390/antiox13070769
Chicago/Turabian Style
Stairley, Rebecca A., Allison M. Trouten, Shuang Li, Patrick L. Roddy, Kristine Y. DeLeon-Pennell, Kyu-Ho Lee, Henry M. Sucov, Chun Liu, and Ge Tao.
2024. "Anti-Ferroptotic Treatment Deteriorates Myocardial Infarction by Inhibiting Angiogenesis and Altering Immune Response" Antioxidants 13, no. 7: 769.
https://doi.org/10.3390/antiox13070769
APA Style
Stairley, R. A., Trouten, A. M., Li, S., Roddy, P. L., DeLeon-Pennell, K. Y., Lee, K.-H., Sucov, H. M., Liu, C., & Tao, G.
(2024). Anti-Ferroptotic Treatment Deteriorates Myocardial Infarction by Inhibiting Angiogenesis and Altering Immune Response. Antioxidants, 13(7), 769.
https://doi.org/10.3390/antiox13070769